medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-12-115-121medsovet-3142Research ArticleЭндокринологияEndocrinologyРанняя комбинированная терапия сахарного диабета 2-го типа. Время новых решенийEarly combination therapy for type 2 diabetes. Time for new decisionshttps://orcid.org/0000-0002-9960-524XКондратьеваЛ. В.KondratyevaL. V.

Кондратьева Лариса Васильевна - кандидат медицинских наук, доцент.

125993, Москва, ул. Баррикадная, д. 2/1, стр. 1;тел.: +7(916) 544-55-90

Kondratyeva Larisa Vasilyevna - Cand. of Sci. (Med.), Associate Professor.

125993, Moscow, Barrikadnaya St., 2/1, b. 1; Tel.: +7(916) 544-55-90

Kondratieva88@mail.ruФедеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationRussian Federation201930082019012115121Copyright © Кондратьева Л.В., 20192019Кондратьева Л.В.Kondratyeva L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3142

Заболеваемость сахарным диабетом неуклонно возрастает во всем мире. Большую часть заболевших составляют пациенты с сахарным диабетом 2-го типа, многие из которых уже при установлении диагноза имеют осложнения. Стратегия и определение тактики лечения пациентов с СД2 сегодня являются одними из приоритетных задач современной медицины.

The morbidity of diabetes mellitus is steadily increasing worldwide. Most of the patients with type 2 diabetes, many of whom already have complications when diagnosed. Strategy and tactics of treatment of patients with DM2 today are one of the priorities of modern medicine.

сахарный диабет 2-го типасахароснижающая терапияранняя комбинированная терапияфиксированная комбинация метформина и ингибитора ДПП-4Type 2 diabetes mellitushypoglycemic therapyearly combination therapyfixed-dose combination Metformin and DPP-4 inhibitorReferencesIDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas8th-edition.html.IDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas8th-edition.html.Carls G., Huynh J., Tuttle E. et al. Achivment of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes ther. 2017;8(4):863-873. doi:10.1007/s13300-017-0280-5.Carls G., Huynh J., Tuttle E. et al. Achivment of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes ther. 2017;8(4):863-873. doi:10.1007/s13300-017-0280-5.Hu F.B., Stampfer MJ., Haffiier S.M., Solomon C.G., Willett W.C., Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002 Jul;25(7):1129-1134.Hu F.B., Stampfer MJ., Haffiier S.M., Solomon C.G., Willett W.C., Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002 Jul;25(7):1129-1134.Reaven G.M. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 1992;41(5), Suppl. 1:16-19.Reaven G.M. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 1992;41(5), Suppl. 1:16-19.Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am. J. Med. 1998;105(1A):4S-14.Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am. J. Med. 1998;105(1A):4S-14.Morrish NJ., Wang S.L., Stevens L.K., Fuller J.H. et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(2):14-21.Morrish NJ., Wang S.L., Stevens L.K., Fuller J.H. et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(2):14-21.Budoff MJ. Not all diabetics are created equal (in cardiovascular risk). Eur. Heart J. 2008;29(18):2193-2194.Budoff MJ. Not all diabetics are created equal (in cardiovascular risk). Eur. Heart J. 2008;29(18):2193-2194.Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. The New England Journal of Medicine. 1998;339:229-34. https://doi.org/10.1056/NEJM199807233390404.Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. The New England Journal of Medicine. 1998;339:229-34. https://doi.org/10.1056/NEJM199807233390404.Дедов И.И., Шестакова М.В., Александров А.А. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Сахарный диабет. Приложение. 2011;3.Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Algorithms for specialized medical care in diabetes mellitus (5th edition). Sakharnyi Diabet. Prilozhenie. 2011;3. (In Russ.)Дедов И.И., Шестакова, М.В., Майоров А. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Сахарный диабет. 2017;8:1-112. doi: 1014341/DM20171S8.Dedov I.I., Shestakova M.V., Maiorov A. Algorithms for specialized medical care in diabetes mellitus. 8th edition. Sakharnyi Diabet. 2017;8:1-112. doi: 1014341/DM20171S8. (In Russ.)International Diabetes Federation (IDF) Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017.International Diabetes Federation (IDF) Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017.Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 2019;(9):20.Dedov I.I., Shestakova M.V., Maiorov A.Yu. Algorithms for specialized medical care in diabetes mellitus. 2019; 9th edition: 20. (In Russ.)Khunti K., Wolden M.L., Thorsted B.L. et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.Khunti K., Wolden M.L., Thorsted B.L. et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.Inzucchi S.E., Bergenstral R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149. doi: 10.2337/dc14-2441.16.Inzucchi S.E., Bergenstral R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149. doi: 10.2337/dc14-2441.16.Turner R.C. et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). JAMA. 1999;281(21):2005-12.Turner R.C. et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). JAMA. 1999;281(21):2005-12.UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.Liu Y, Hong T. Combination therapy of dipepti-dyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2014;16(2):111-117. https://doi.org/10.1111/dom.12128. Epub 2013 Jun 3.Liu Y, Hong T. Combination therapy of dipepti-dyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2014;16(2):111-117. https://doi.org/10.1111/dom.12128. Epub 2013 Jun 3.Wu D., Li L., Liu C. Efficacy and safety of dipep-tidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30-37. https//doi.org/10.1111/dom.12174. Epub 2013 Jul 16.Wu D., Li L., Liu C. Efficacy and safety of dipep-tidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30-37. https://doi.org/10.1111/dom.12174. Epub 2013 Jul 16.Bianchi C., Daniele G., Dardano A., Miccoli R., Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2. Diabetes. Drugs. 2017; 77(3):247-264.Bianchi C., Daniele G., Dardano A., Miccoli R., Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2. Diabetes. Drugs. 2017; 77(3):247-264.Cho Y.M., Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer. Diabetologia. 2011;54(2):219-222.Cho Y.M., Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer. Diabetologia. 2011;54(2):219-222.Davies MJ., DAlessio D.A., Fradkin J., Kerman W.N. et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. https://doi.org/10.2337/dci18-0033.Davies MJ., DAlessio D.A., Fradkin J., Kerman W.N. et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. https://doi.org/10.2337/dci18-0033.Capuano A., Giugliano D., Sportiello L. et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001. http://dx.doi.org/10.2147/DDDT.S37647.Capuano A., Giugliano D., Sportiello L. et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001. http://dx.doi.org/10.2147/DDDT.S37647.Nauck M.A, Ellis G.C, Fleck P.R, Wilson C.A, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.Nauck M.A, Ellis G.C, Fleck P.R, Wilson C.A, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.Bosi E., Ellis G.C, Wilson C.A, Fleck P.R. Alogliptin as a third oral antidiabeticdrug in patients with type 2 diabetes and inadequate glycaemic control onmetformin and pioglita-zone: a 52-week, randomized, double-blind, activecontrolled, parallel-group study. Diabetes Obes Metab. 2011;13:1088-1096.Bosi E., Ellis G.C, Wilson C.A, Fleck P.R. Alogliptin as a third oral antidiabeticdrug in patients with type 2 diabetes and inadequate glycaemic control onmetformin and pioglita-zone: a 52-week, randomized, double-blind, activecontrolled, parallel-group study. Diabetes Obes Metab. 2011;13:1088-1096.Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145-1152.Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145-1152.Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076.Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076.Российское общество эндокринологов. Применение препарата алоглиптин бензоат (Випидия®) при терапии пациентов с сахарным диабетом 2 типа в реальной клинической практике на территории РФ. Анонс результатов промежуточного анализа. Сахарный диабет. 2018;21(5).Russian Society of Endocrinologists. Administration of aloglip-tin benzoate (Vipidia®) for the treatment of patients with type 2 diabetes in real clinical practice in the Russian Federation. Announcements of interim analyses. Sakharnyi Diabet. 2018;21(5). (In Russ.)Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.Phung OJ., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410-1418.Phung OJ., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410-1418.Del Prato S., Camisasca R., Wilson C., Fleck P Durability of the efficacy and safety of aloglip-tin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239-1246.Del Prato S., Camisasca R., Wilson C., Fleck P Durability of the efficacy and safety of aloglip-tin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239-1246.Bianchi C. et al. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017; 77:247-264. doi: 10.1007/s40265-017-0694-4.Bianchi C. et al. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017; 77:247-264. doi: 10.1007/s40265-017-0694-4.

The authors declare that there are no conflicts of interest present.